Detailed Narrative
Strong Q4 FY26 Performance Driven by International Formulations
Indoco Remedies reported a significant turnaround in Q4 FY26, achieving positive performance after six quarters. Consolidated net revenues grew 18.8% YoY to INR 4,559 million, while standalone net revenues increased by 25.8% YoY to INR 4,291 million. This growth was primarily fueled by the international formulations business, which saw a remarkable 94.6% YoY acceleration to INR 2,147 million. Consolidated EBITDA margin improved substantially to 10.9% (INR 497 million) from a negative 0.2% (negative 8 million) in the prior year, reflecting enhanced profitability.
International Markets Show Robust Growth Across Geographies
The company's international business demonstrated strong momentum across key regions. Regulated markets grew 78.3% to INR 1,401 million, with the US business expanding 77.5% to INR 546 million and Europe growing 68.7% to INR 786 million. Emerging markets also delivered exceptional growth, surging 134% to INR 746 million. This broad-based international performance was supported by new ANDA approvals for liquid orals (Brivaracetam and Lacosamide) in the US and a decent order book in Europe.
Domestic Business Muted by Seasonality and Receivables Concerns
In contrast to international growth, the India business experienced muted performance in Q4, with domestic formulation revenue at INR 1,739 million. This was attributed to seasonal factors impacting segments like anti-infectives and respiratory, leading stockists to reduce inventory despite underlying strong prescription growth. A key concern raised was the elongation of standalone trade receivables, which grew 45% against a 9% revenue increase, primarily due to longer credit periods in international and emerging markets.
Strategic Portfolio Shifts and API Business Challenges
Indoco Remedies strategically hived off its ophthal business in India and Africa to Sunway, aiming to focus on core ethical business areas. Management clarified this was a strategic move, not driven by liquidity needs, as the ophthal division was small (INR 37 crore in India). The API business, however, faced challenges, de-growing by 23% to INR 315 million. This decline is linked to products being under validation and not yet approved for sales, which is currently impacting the financials of Warren Remedies, with regulatory approval expected in about one more year.
Debt Management and Capital Allocation Priorities
The company's consolidated debt stands at INR 960 crore, with a commitment to repay INR 140 crore annually for the next three years. An INR 24 crore exchange loss on a 10 million euro ECB loan significantly contributed to finance costs this quarter. Management emphasized tight control on CAPEX, with no major CAPEX plans for the next two years, and efforts to reduce operating expenses. An idle land parcel worth INR 23 crore is also classified as held for sale.
New Launches and Future Growth Drivers
New product launches in India contributed over INR 2 crore in Q4 and INR 20 crore for the full year, including products like Cyclopam AC suspension. The company plans to launch liquid orals in both Europe and the US this year, targeting less crowded market segments to drive future growth. Management expressed high confidence in the emerging markets business for the next 2-3 years and expects Europe contract manufacturing to yield better margins in the coming year as plants complete MMP scale-ups.